Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

402

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 8 drugs with upcoming expirations

Activity

Key Events

May 28, 2025FDACortef — KHINDIVI

Jun 27, 2023FDANGENLA — NGENLA

Feb 1, 2023FDALipitor — ATORVALIQ

Dec 13, 2022FDAXalatan — IYUZEH

Jan 30, 2021TrialA Bioequivalence Study of Sildenafil Citrate Orally-Disintegrating Film Dosage Form

Sep 29, 2020FDACortef — ALKINDI SPRINKLE

Dec 17, 2019TrialAn Bioequivalence Study Comparing Nicergoline 10 mg Tablet Manufactured in China With Nicergoline 10 mg Tablet Manufactured in Italy Under Fasted and Fed Conditions in Healthy Chinese Participants

Aug 14, 2019FDATB Alliance — PRETOMANID

4 more events

Jul 23, 2019FDARUXIENCE — RUXIENCE

Jun 27, 2019FDAZIRABEV — ZIRABEV

Dec 21, 2018TrialExtension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder

Nov 6, 2018TrialRelative Bioavailability Study of Zoloft Oral Solution to Zoloft Tablets

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

18 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Lyrica3 patentsNov 2, 2026 Lyrica3 patentsMay 2, 2027 VibramycinDec 19, 2027 DoryxFeb 3, 2028 DeltasoneOct 11, 2028 XalatanOct 15, 2028 YupelriOct 31, 2028 XalatanSep 12, 2029

10 more

Yupelri5 patentsJul 14, 2030 XalatanJul 8, 2031 YupelriAug 25, 2031 CortefNov 19, 2032 CortefJan 10, 2033 CortefMay 12, 2034 Doryx3 patentsOct 23, 2034 Lipitor6 patentsJun 7, 2037 Yupelri3 patentsAug 29, 2039 Cortef2 patentsFeb 23, 2043

Regulatory

Regulatory Timeline

20071 event

FDAApr 27

Zithromax — AZASITE

Application NDA050810 (NDA)

20081 event

FDAJan 17

Deltasone — FLO-PRED

Application NDA022067 (NDA)

20101 event

FDAJan 4

Lyrica — LYRICA

Application NDA022488 (NDA)

20121 event

FDAMay 1

ELELYSO — ELELYSO

Application BLA022458 (BLA)

20142 events

FDADec 19

Doryx — DORYX

Application NDA050795 (NDA)

FDAJul 25

Doryx — ACTICLATE

Application NDA205931 (NDA)

20162 events

FDAApr 26

Doryx — ACTICLATE CAP

Application NDA208253 (NDA)

FDAApr 5

INFLECTRA — INFLECTRA

Application BLA125544 (BLA)

20171 event

FDAOct 11

Lyrica — LYRICA CR

Application NDA209501 (NDA)

20183 events

FDANov 9

Yupelri — YUPELRI

Application NDA210598 (NDA)

FDASep 12

Xalatan — XELPROS

Application NDA206185 (NDA)

FDAJun 15

Doryx — LYMEPAK

Application NDA209844 (NDA)

20193 events

FDAAug 14

TB Alliance — PRETOMANID

Application NDA212862 (NDA)

FDAJul 23

RUXIENCE — RUXIENCE

Application BLA761103 (BLA)

FDAJun 27

ZIRABEV — ZIRABEV

Application BLA761099 (BLA)

20201 event

FDASep 29

Cortef — ALKINDI SPRINKLE

Application NDA213876 (NDA)

20221 event

FDADec 13

Xalatan — IYUZEH

Application NDA216472 (NDA)

20232 events

FDAJun 27

NGENLA — NGENLA

Application BLA761184 (BLA)

FDAFeb 1

Lipitor — ATORVALIQ

Application NDA213260 (NDA)

20251 event

FDAMay 28

Cortef — KHINDIVI

Application NDA218980 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)